Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease Among Adults With HIV-United States, 2008-2018

被引:3
|
作者
Kobayashi, Miwako [1 ]
Matanock, Almea [1 ]
Xing, Wei [2 ]
Adih, William K. [3 ]
Li, Jianmin [3 ]
Gierke, Ryan [1 ]
Almendares, Olivia [1 ]
Reingold, Arthur [4 ]
Alden, Nisha [5 ]
Petit, Susan [6 ]
Farley, Monica M. [7 ,8 ]
Harrison, Lee H. [9 ]
Holtzman, Corinne [10 ]
Baumbach, Joan [11 ]
Thomas, Ann [12 ]
Schaffner, William [13 ]
McGee, Lesley [1 ]
Pilishvili, Tamara [1 ]
机构
[1] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA
[2] Weems Design Studio Inc, Decatur, GA USA
[3] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30329 USA
[4] Univ Calif Berkeley, Berkeley Sch Publ Hlth, Berkeley, CA 94720 USA
[5] Colorado Dept Publ Hlth & Environm, Denver, CO USA
[6] Connecticut Dept Publ Hlth, Hartford, CT USA
[7] Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA
[8] Atlanta VA Med Ctr, Atlanta, GA USA
[9] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA
[10] Minnesota Dept Hlth, St Paul, MN USA
[11] New Mexico Dept Hlth, Santa Fe, NM USA
[12] Oregon Dept Human Serv, Portland, OR USA
[13] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA
关键词
13-valent pneumococcal conjugate vaccine; invasive pneumococcal disease; indirect effects; direct effects; HIV infection; STREPTOCOCCUS-PNEUMONIAE INFECTIONS; POLYSACCHARIDE VACCINE; ANTIRETROVIRAL THERAPY; ADVISORY-COMMITTEE; RACIAL DISPARITIES; RISK-FACTORS; ERA; RECOMMENDATIONS; PREVENTION; RESPONSES;
D O I
10.1097/QAI.0000000000002916
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: People with HIV (PWH) are at increased risk for invasive pneumococcal disease (IPD). Thirteen-valent pneumococcal conjugate vaccine (PCV13) was recommended for use in US children in 2010 and for PWH aged 19 years or older in 2012. We evaluated the population-level impact of PCV13 on IPD among PWH and non-PWH aged 19 years or older. Methods: We identified IPD cases from 2008 to 2018 through the Active Bacterial Core surveillance platform. We estimated IPD incidence using the National HIV Surveillance System and US Census Bureau data. We measured percent changes in IPD incidence from 2008 to 2009 to 2017-2018 by HIV status, age group, and vaccine serotype group, including serotypes in recently licensed 15-valent (PCV15) and 20-valent (PCV20) PCVs. Results: In 2008-2009 and 2017-2018, 8.4% (552/6548) and 8.0% (416/5169) of adult IPD cases were among PWH, respectively. Compared with non-PWH, a larger proportion of IPD cases among PWH were in adults aged 19-64 years (94.7%-97.4% vs. 56.0%-60.1%) and non-Hispanic Black people (62.5%-73.0% vs. 16.7%-19.2%). Overall and PCV13-type IPD incidence in PWH declined by 40.3% (95% confidence interval: -47.7 to -32.3) and 72.5% (95% confidence interval: -78.8 to -65.6), respectively. In 2017-2018, IPD incidence was 16.8 (overall) and 12.6 (PCV13 type) times higher in PWH compared with non-PWH; PCV13, PCV15/non-PCV13, and PCV20/non-PCV15 serotypes comprised 21.5%, 11.2%, and 16.5% of IPD in PWH, respectively. Conclusions: Despite reductions post-PCV13 introduction, IPD incidence among PWH remained substantially higher than among non-PWH. Higher-valent PCVs provide opportunities to reduce remaining IPD burden in PWH.
引用
收藏
页码:6 / 14
页数:9
相关论文
共 50 条
  • [1] Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults
    Gladstone, Rebecca A.
    Jefferies, Johanna M.
    Faust, Saul N.
    Clarke, Stuart C.
    EXPERT REVIEW OF VACCINES, 2012, 11 (08) : 889 - 902
  • [2] Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions-United States
    Ahmed, Sana S.
    Pondo, Tracy
    Xing, Wei
    McGee, Lesley
    Farley, Monica
    Schaffner, William
    Thomas, Ann
    Reingold, Arthur
    Harrison, Lee H.
    Lynfield, Ruth
    Rowlands, Jemma
    Bennett, Nancy
    Petit, Susan
    Barnes, Meghan
    Smelser, Chad
    Beall, Bernard
    Whitney, Cynthia G.
    Pilishvili, Tamara
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (12) : 2484 - 2492
  • [3] Invasive pneumococcal disease after implementation of 13-valent pneumococcal conjugate vaccine
    Kyprianidou, S-A.
    Mejbri, M.
    Tornay, A. A.
    Natterer, J.
    Greub, G.
    Crisinel, P-A.
    Asner, S.
    SWISS MEDICAL WEEKLY, 2014, 144 : 42S - 43S
  • [4] Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
    Nikolova, Kristiana Alexandrova
    Andersson, Mikael
    Slotved, Hans-Christian
    Koch, Anders
    VACCINES, 2021, 9 (10)
  • [5] Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
    McLaughlin, John M.
    Swerdlow, David L.
    Khan, Farid
    Will, Oliver
    Curry, Aaron
    Snow, Vincenza
    Isturiz, Raul E.
    Jodar, Luis
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 841 - 849
  • [6] Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska
    Bruce, Michael G.
    Singleton, Rosalyn
    Bulkow, Lisa
    Rudolph, Karen
    Zulz, Tammy
    Gounder, Prabhu
    Hurlburt, Debby
    Bruden, Dana
    Hennessy, Thomas
    VACCINE, 2015, 33 (38) : 4813 - 4819
  • [7] Infants at Risk for Invasive Pneumococcal Disease in the 13-Valent Pneumococcal Conjugate Vaccine Era
    Yildirim, Inci
    Pelton, Stephen I.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (01) : 91 - 92
  • [8] Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage Among American Indians
    Grant, Lindsay R.
    Hammitt, Laura L.
    O'Brien, Sarah E.
    Jacobs, Michael R.
    Donaldson, Connie
    Weatherholtz, Robert C.
    Reid, Raymond
    Santosham, Mathuram
    O'Brien, Katherine L.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (08) : 907 - 914
  • [9] Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults
    Hsiao, Amber
    Lewis, Ned
    Hansen, John
    Timbol, Julius
    Suaya, Jose A.
    Alexander-Parrish, Ronika
    Grant, Lindsay R.
    Gessner, Bradford D.
    Klein, Nicola P.
    VACCINE, 2025, 44
  • [10] Invasive Pneumococcal Disease After Implementation of 13-Valent Conjugate Vaccine
    Tam, Pui-Ying Iroh
    Madoff, Lawrence C.
    Coombes, Brandon
    Pelton, Stephen I.
    PEDIATRICS, 2014, 134 (02) : 210 - 217